{"title":"Pevaryl","description":"\u003cp\u003ePevaryl a base di econazolo, antimicotico contro funghi e lieviti della pelle e delle mucose. Disponibile in crema, polvere cutanea, soluzione in bustine monodose, soluzione per i genitali esterni e ovuli vaginali. Per micosi cutanee, piede d’atleta e candidosi. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"pevaryl-1-60-ml-soluzione-cutanea-genitali-esterni","title":"Pevaryl 1% 60 ml cutaneous solution external genitalia","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVulvovaginal mycosis Mycotic balanitis\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL 1% vaginal cream 100 g of vaginal cream contain: active ingredient: econazole nitrate 1g. Excipients with known effect: This medicinal product contains butylated hydroxyanisole and benzoic acid. PEVARYL 50 mg ovules 1 ovule contains: active ingredient: econazole nitrate 50 mg. PEVARYL 150 mg ovules 1 ovule contains: active ingredient: econazole nitrate 150 mg. PEVARYL 150 mg prolonged-release ovules 1 prolonged-release ovule contains: active ingredient: econazole micronized nitrate 150 mg. PEVARYL 1% cutaneous solution for external genitalia 100 ml of cutaneous solution for external genitalia contains: active ingredient: econazole 1.033 g. Excipients with known effect: This medicinal product contains benzyl alcohol and linalool (as fragrance in perfume). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eVaginal cream:\u003c\/u\u003e \u003c\/i\u003e mixture of stearic acid esters with glycols; mixture of fatty acids with macrogol; Vaseline oil; \u003cb\u003eButylated hydroxyanisole\u003c\/b\u003e; \u003cb\u003ebenzoic acid\u003c\/b\u003e; purified water. \u003ci\u003e \u003cu\u003eOvules 50 mg:\u003c\/u\u003e \u003c\/i\u003e blend of synthetic triglycerides; mixture of synthetic glycerides. \u003ci\u003e \u003cu\u003eOvules 150 mg:\u003c\/u\u003e \u003c\/i\u003e blend of synthetic triglycerides; mixture of synthetic glycerides. \u003ci\u003e \u003cu\u003eProlonged-release ovules 150 mg:\u003c\/u\u003e \u003c\/i\u003e galactomannan polysaccharide; colloidal silica; saturated fatty acid triglyceride mixture; blend of synthetic triglycerides; \u003cb\u003estearyl heptanoate\u003c\/b\u003e. \u003ci\u003e \u003cu\u003eSkin solution for external genitalia:\u003c\/u\u003e \u003c\/i\u003e polysorbate 20; \u003cb\u003ebenzyl alcohol\u003c\/b\u003e; sorbitan monolaurate; N-[2-hydroxyethyl] -N-[2-(laurylamino)-ethyl] -aminoacetic acid sodium salt of 3,6,9-trioxadocosylsulfate; macrogol 6000 distearate; lactic acid; \u003cb\u003eperfume n.4074\u003c\/b\u003e; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePevaryl is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients, listed in section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eWomen\u003c\/b\u003e. \u003ci\u003e \u003cu\u003eVaginal cream:\u003c\/u\u003e \u003c\/i\u003e 1 applicator (5 cc) filled with vaginal cream inserted into the vagina for 15 days every evening before bedtime. The treatment must be continued even after the disappearance of the subjective complaints (itching, leukorrhea). \u003cu\u003e \u003ci\u003e50 mg ovules:\u003c\/i\u003e \u003c\/u\u003e 1 egg inserted deeply into the vagina, preferably in a supine position, every evening for 15 days. The treatment must be continued even after the disappearance of the subjective complaints (itching, leukorrhea). \u003ci\u003e \u003cu\u003e150 mg ovules:\u003c\/u\u003e \u003c\/i\u003e 1 egg inserted deeply into the vagina, preferably in a supine position, every evening for three consecutive days. In case of relapse or if the control culture test is positive one week after treatment, a second cycle of therapy will be repeated. \u003ci\u003e \u003cu\u003e150mg Extended Release Ovules:\u003c\/u\u003e \u003c\/i\u003e the therapy involves a one-day treatment and consists of inserting one egg deeply into the vagina, preferably in a supine position, one egg in the morning and one in the evening. \u003ci\u003e \u003cu\u003eSkin solution for external genitalia:\u003c\/u\u003e \u003c\/i\u003e this pharmaceutical form is a suitable complement to therapy with ovules or vaginal cream. Cleanse the external genitalia with 10 cc (1 dose) of solution dissolved in warm water. The treatment can be carried out once or twice a day. \u003cb\u003eMen: \u003c\/b\u003e Wash and dry the penis and then apply the cream to the glans and foreskin once a day for 15 consecutive days. \u003cb\u003e \u003cu\u003eInstructions for use.\u003c\/u\u003e \u003c\/b\u003e \u003ci\u003eCream\u003c\/i\u003e: Fill the applicator: 1. Remove the cap from the tube. 2. Use the tip on the top of the cap to pierce the operculum on the tube. 3. Screw the applicator onto the tube.  4. Press the tube from below and fill the applicator until the piston stops. If the piston offers some resistance, pull it gently. Unless otherwise prescribed by your doctor, the applicator must be completely filled.  5. Unscrew the applicator from the tube. Place the cap back on the tube. To use the applicator: 1. In a lying position, keep your knees bent and spread apart. 2. Holding the applicator at the end of the cannula, insert the filled applicator into the vagina as far as it feels comfortable. 3. Slowly push the piston to release the cream into the vagina. 4. Remove the applicator from the vagina and throw it away (but not down the toilet). \u003cb\u003eChildren (2-16 years)\u003c\/b\u003e: Safety and effectiveness in children has not been established. \u003cb\u003eElderly\u003c\/b\u003e: There are insufficient data on the use of PEVARYL in elderly patients over 65 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOva and extended-release ovules: do not store above 30°C. Vaginal cream: do not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePevaryl Vaginal Cream and Ovules are for intra-vaginal use only. Pevaryl is not for ophthalmic or oral use. Concomitant use of latex condoms or diaphragms with vaginal antimicrobial preparations may decrease the effectiveness of the latex contraceptive. Therefore, products such as PEVARYL should not be used together with diaphragms or latex condoms. Patients using spermicides should consult their doctor as any local vaginal treatment may make the spermicide inactive. PEVARYL must not be used together with other products for the treatment, internal or external, of the genitals. If marked irritation or sensitization occurs, treatment should be discontinued. Patients sensitive to imidazoles may be sensitive to econazole nitrate. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e: PEVARYL 1% vaginal cream contains butylated hydroxyanisole. May cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. PEVARYL 1% vaginal cream contains benzoic acid. This medicine contains 10 mg of benzoic acid in each applicator equivalent to 2 mg\/ g of cream. Benzoic acid may cause local irritation. PEVARYL 1% cutaneous solution for external genitalia contains benzyl alcohol. This medicinal product contains 10.33 mg of benzyl alcohol per dose (10 cc) which is equivalent to 1.03 mg\/ml of solution. Benzyl alcohol may cause allergic reactions. Benzyl alcohol may cause mild local irritation. PEVARYL 1% cutaneous solution for external genitalia contains linalool. This medicine contains fragrance with linalool. Linalool can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEconazole is a known inhibitor of cytochromes CYP3A4 and CYP2C9. Despite the limited systemic availability of the product after vaginal application (see section 5.2 Pharmacokinetic properties) clinically relevant interactions may occur and have been reported in patients receiving oral anticoagulants. Caution should be used in patients taking oral anticoagulants such as warfarin or acenocoumarol and the anticoagulant effect should be monitored. A dosage adjustment of the oral anticoagulant drug may be necessary during treatment with econazole and after its discontinuation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe safety of Pevaryl gynecological formulations was evaluated on 3630 patients in 32 clinical studies. Based on the safety data collected from these clinical studies, the most commonly reported adverse drug reactions (Adverse Drug Reactions, ADRs) (incidence ≥ 1%) were (with incidence%): pruritus (1.2%) and burning sensation of the skin (1.2%). The table below reports the ADRs of the gynecological formulations of PEVARYL, deriving from both clinical studies and post-marketing experience, including the adverse reactions already reported above. Frequencies are reported according to the following convention: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥1\/1,000, \u003c1\/100); Rare (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000), Not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1: Adverse Drug Reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse drug reactions: Frequency.\u003c\/p\u003e\n\u003cp\u003eSystem Organ Class - Adverse drug reactions: Common. Uncommon. Rare. Not Known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse drug reactions: Itching, burning sensation of the skin. Rash. Erythema. Angioedema, Urticaria, Contact dermatitis, Skin exfoliation.\u003c\/p\u003e\n\u003cp\u003eReproductive system and breast disorders - Vulvovaginal burning sensation.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Application site pain, Application site irritation, Application site swelling.\u003c\/p\u003e\n\u003cp\u003eFurthermore, cases of local allergic reactions have been reported. With the cutaneous solution, in particular, local sensitization phenomena may occur. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse events associated with overdose or misuse of PEVARYL should be consistent with the adverse drug reactions listed in section 4.8 (Undesirable effects). Pevaryl is for topical use only. In case of accidental ingestion, treat with symptomatic therapy. If the product is accidentally applied to the eyes, wash with clean or saline water and consult a doctor if symptoms persist.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e: Animal studies have shown reproductive toxicity (see section 5.3). Due to vaginal absorption, PEVARYL should not be used in the first trimester of pregnancy unless the doctor considers it necessary for the patient's health. PEVARYL can be used during the second and third trimesters if the potential benefits outweigh the possible risks to the fetus. \u003cu\u003eBreastfeeding:\u003c\/u\u003e After oral administration of econazole nitrate to lactating rats, econazole and its metabolites were excreted in milk and were found in the pups. It is not known whether econazole nitrate is excreted in human milk. Use PEVARYL with caution in breastfeeding patients. \u003cu\u003eFertility\u003c\/u\u003e: Results from reproduction studies conducted in animals showed no effects on fertility (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone known.\u003c\/p\u003e","brand":"Karo Pharma","offers":[{"title":"Default Title","offer_id":51730203443527,"sku":"023603184","price":17.14,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/karo-pharma-srl-pevaryl-1-60-ml-soluzione-cutanea-genitali-esterni-farmacia-dottor-tili-1213791425.jpg?v=1767138647"},{"product_id":"pevaryl-150-mg-6-ovuli","title":"Pevaryl 150 mg 6 ovules","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVulvovaginal mycosis Mycotic balanitis\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL 1% vaginal cream 100 g of vaginal cream contain: active ingredient: econazole nitrate 1g. Excipients with known effect: This medicinal product contains butylated hydroxyanisole and benzoic acid. PEVARYL 50 mg ovules 1 ovule contains: active ingredient: econazole nitrate 50 mg. PEVARYL 150 mg ovules 1 ovule contains: active ingredient: econazole nitrate 150 mg. PEVARYL 150 mg prolonged-release ovules 1 prolonged-release ovule contains: active ingredient: econazole micronized nitrate 150 mg. PEVARYL 1% cutaneous solution for external genitalia 100 ml of cutaneous solution for external genitalia contains: active ingredient: econazole 1.033 g. Excipients with known effect: This medicinal product contains benzyl alcohol and linalool (as fragrance in perfume). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eVaginal cream:\u003c\/u\u003e \u003c\/i\u003e mixture of stearic acid esters with glycols; mixture of fatty acids with macrogol; Vaseline oil; \u003cb\u003eButylated hydroxyanisole\u003c\/b\u003e; \u003cb\u003ebenzoic acid\u003c\/b\u003e; purified water. \u003ci\u003e \u003cu\u003eOvules 50 mg:\u003c\/u\u003e \u003c\/i\u003e blend of synthetic triglycerides; mixture of synthetic glycerides. \u003ci\u003e \u003cu\u003eOvules 150 mg:\u003c\/u\u003e \u003c\/i\u003e blend of synthetic triglycerides; mixture of synthetic glycerides. \u003ci\u003e \u003cu\u003eProlonged-release ovules 150 mg:\u003c\/u\u003e \u003c\/i\u003e galactomannan polysaccharide; colloidal silica; saturated fatty acid triglyceride mixture; blend of synthetic triglycerides; \u003cb\u003estearyl heptanoate\u003c\/b\u003e. \u003ci\u003e \u003cu\u003eSkin solution for external genitalia:\u003c\/u\u003e \u003c\/i\u003e polysorbate 20; \u003cb\u003ebenzyl alcohol\u003c\/b\u003e; sorbitan monolaurate; N-[2-hydroxyethyl] -N-[2-(laurylamino)-ethyl] -aminoacetic acid sodium salt of 3,6,9-trioxadocosylsulfate; macrogol 6000 distearate; lactic acid; \u003cb\u003eperfume n.4074\u003c\/b\u003e; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePevaryl is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients, listed in section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eWomen\u003c\/b\u003e. \u003ci\u003e \u003cu\u003eVaginal cream:\u003c\/u\u003e \u003c\/i\u003e 1 applicator (5 cc) filled with vaginal cream inserted into the vagina for 15 days every evening before bedtime. The treatment must be continued even after the disappearance of the subjective complaints (itching, leukorrhea). \u003cu\u003e \u003ci\u003e50 mg ovules:\u003c\/i\u003e \u003c\/u\u003e 1 egg inserted deeply into the vagina, preferably in a supine position, every evening for 15 days. The treatment must be continued even after the disappearance of the subjective complaints (itching, leukorrhea). \u003ci\u003e \u003cu\u003e150 mg ovules:\u003c\/u\u003e \u003c\/i\u003e 1 egg inserted deeply into the vagina, preferably in a supine position, every evening for three consecutive days. In case of relapse or if the control culture test is positive one week after treatment, a second cycle of therapy will be repeated. \u003ci\u003e \u003cu\u003e150mg Extended Release Ovules:\u003c\/u\u003e \u003c\/i\u003e the therapy involves a one-day treatment and consists of inserting one egg deeply into the vagina, preferably in a supine position, one egg in the morning and one in the evening. \u003ci\u003e \u003cu\u003eSkin solution for external genitalia:\u003c\/u\u003e \u003c\/i\u003e this pharmaceutical form is a suitable complement to therapy with ovules or vaginal cream. Cleanse the external genitalia with 10 cc (1 dose) of solution dissolved in warm water. The treatment can be carried out once or twice a day. \u003cb\u003eMen: \u003c\/b\u003e Wash and dry the penis and then apply the cream to the glans and foreskin once a day for 15 consecutive days. \u003cb\u003e \u003cu\u003eInstructions for use.\u003c\/u\u003e \u003c\/b\u003e \u003ci\u003eCream\u003c\/i\u003e: Fill the applicator: 1. Remove the cap from the tube. 2. Use the tip on the top of the cap to pierce the operculum on the tube. 3. Screw the applicator onto the tube.  4. Press the tube from below and fill the applicator until the piston stops. If the piston offers some resistance, pull it gently. Unless otherwise prescribed by your doctor, the applicator must be completely filled.  5. Unscrew the applicator from the tube. Place the cap back on the tube. To use the applicator: 1. In a lying position, keep your knees bent and spread apart. 2. Holding the applicator at the end of the cannula, insert the filled applicator into the vagina as far as it feels comfortable. 3. Slowly push the piston to release the cream into the vagina. 4. Remove the applicator from the vagina and throw it away (but not down the toilet). \u003cb\u003eChildren (2-16 years)\u003c\/b\u003e: Safety and effectiveness in children has not been established. \u003cb\u003eElderly\u003c\/b\u003e: There are insufficient data on the use of PEVARYL in elderly patients over 65 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOva and extended-release ovules: do not store above 30°C. Vaginal cream: do not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePevaryl Vaginal Cream and Ovules are for intra-vaginal use only. Pevaryl is not for ophthalmic or oral use. Concomitant use of latex condoms or diaphragms with vaginal antimicrobial preparations may decrease the effectiveness of the latex contraceptive. Therefore, products such as PEVARYL should not be used together with diaphragms or latex condoms. Patients using spermicides should consult their doctor as any local vaginal treatment may make the spermicide inactive. PEVARYL must not be used together with other products for the treatment, internal or external, of the genitals. If marked irritation or sensitization occurs, treatment should be discontinued. Patients sensitive to imidazoles may be sensitive to econazole nitrate. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e: PEVARYL 1% vaginal cream contains butylated hydroxyanisole. May cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. PEVARYL 1% vaginal cream contains benzoic acid. This medicine contains 10 mg of benzoic acid in each applicator equivalent to 2 mg\/ g of cream. Benzoic acid may cause local irritation. PEVARYL 1% cutaneous solution for external genitalia contains benzyl alcohol. This medicinal product contains 10.33 mg of benzyl alcohol per dose (10 cc) which is equivalent to 1.03 mg\/ml of solution. Benzyl alcohol may cause allergic reactions. Benzyl alcohol may cause mild local irritation. PEVARYL 1% cutaneous solution for external genitalia contains linalool. This medicine contains fragrance with linalool. Linalool can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEconazole is a known inhibitor of cytochromes CYP3A4 and CYP2C9. Despite the limited systemic availability of the product after vaginal application (see section 5.2 Pharmacokinetic properties) clinically relevant interactions may occur and have been reported in patients receiving oral anticoagulants. Caution should be used in patients taking oral anticoagulants such as warfarin or acenocoumarol and the anticoagulant effect should be monitored. A dosage adjustment of the oral anticoagulant drug may be necessary during treatment with econazole and after its discontinuation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe safety of Pevaryl gynecological formulations was evaluated on 3630 patients in 32 clinical studies. Based on the safety data collected from these clinical studies, the most commonly reported adverse drug reactions (Adverse Drug Reactions, ADRs) (incidence ≥ 1%) were (with incidence%): pruritus (1.2%) and burning sensation of the skin (1.2%). The table below reports the ADRs of the gynecological formulations of PEVARYL, deriving from both clinical studies and post-marketing experience, including the adverse reactions already reported above. Frequencies are reported according to the following convention: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥1\/1,000, \u003c1\/100); Rare (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000), Not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1: Adverse Drug Reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse drug reactions: Frequency.\u003c\/p\u003e\n\u003cp\u003eSystem Organ Class - Adverse drug reactions: Common. Uncommon. Rare. Not Known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse drug reactions: Itching, burning sensation of the skin. Rash. Erythema. Angioedema, Urticaria, Contact dermatitis, Skin exfoliation.\u003c\/p\u003e\n\u003cp\u003eReproductive system and breast disorders - Vulvovaginal burning sensation.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Application site pain, Application site irritation, Application site swelling.\u003c\/p\u003e\n\u003cp\u003eFurthermore, cases of local allergic reactions have been reported. With the cutaneous solution, in particular, local sensitization phenomena may occur. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse events associated with overdose or misuse of PEVARYL should be consistent with the adverse drug reactions listed in section 4.8 (Undesirable effects). Pevaryl is for topical use only. In case of accidental ingestion, treat with symptomatic therapy. If the product is accidentally applied to the eyes, wash with clean or saline water and consult a doctor if symptoms persist.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e: Animal studies have shown reproductive toxicity (see section 5.3). Due to vaginal absorption, PEVARYL should not be used in the first trimester of pregnancy unless the doctor considers it necessary for the patient's health. PEVARYL can be used during the second and third trimesters if the potential benefits outweigh the possible risks to the fetus. \u003cu\u003eBreastfeeding:\u003c\/u\u003e After oral administration of econazole nitrate to lactating rats, econazole and its metabolites were excreted in milk and were found in the pups. It is not known whether econazole nitrate is excreted in human milk. Use PEVARYL with caution in breastfeeding patients. \u003cu\u003eFertility\u003c\/u\u003e: Results from reproduction studies conducted in animals showed no effects on fertility (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone known.\u003c\/p\u003e","brand":"Karo Pharma","offers":[{"title":"Default Title","offer_id":51730203607367,"sku":"023603107","price":18.85,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/karo-pharma-srl-pevaryl-150-mg-6-ovuli-farmacia-dottor-tili-1213791421.jpg?v=1767138690"},{"product_id":"pevaryl-1-6-bustine-10-g-soluzione-cutanea-non-alcolica","title":"Pevaryl 1% 6 sachets 10 g non-alcoholic cutaneous solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product is indicated in the therapy of: - skin mycosis caused by dermatophytes, yeasts and moulds; - skin infections caused by Gram-positive bacteria: streptococci and staphylococci; - mycotic otitis externa, ear canal mycosis (limited to the skin emulsion form); - onychomycosis; - Pityriasis Versicolor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePevaryl 1% cream 100 g of cream contains: active ingredient: econazole nitrate 1.0 g. Excipients with known effect: This medicinal product contains butylated hydroxyanisole, benzoic acid and linalool as fragrance in the perfume. Pevaryl 1% skin spray, alcoholic solution 100 g of alcoholic skin solution contain: active ingredient: econazole nitrate 1.0 g. Excipients with known effect: This medicinal product contains propylene glycol and linalool as fragrance in the perfume. Pevaryl 1% skin powder 100 g of skin powder contains: active ingredient: econazole nitrate 1.0 g. Excipients with known effect: This medicinal product contains linalool as a fragrance in the perfume. Pevaryl 1% skin emulsion 100 g of skin emulsion contain: active ingredient: econazole nitrate 1.0 g. Excipients with known effect: This medicinal product contains butylated hydroxyanisole, benzoic acid and linalool as fragrance in the perfume. Pevaryl 1% non-alcoholic cutaneous solution 100 g of non-alcoholic cutaneous solution contains: active ingredient: econazole 1.0 g. Excipients with known effect: This medicinal product contains benzyl alcohol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eCream:\u003c\/u\u003e \u003c\/i\u003e Excipients: mixture of stearic acid esters with glycols; mixture of fatty acids with polyethylene glycol; Vaseline oil; \u003cb\u003eButylated hydroxyanisole\u003c\/b\u003e; \u003cb\u003eperfume n.4074\u003c\/b\u003e; \u003cb\u003ebenzoic acid\u003c\/b\u003e; purified water. \u003ci\u003e \u003cu\u003eAlcoholic solution skin spray: \u003c\/u\u003e \u003c\/i\u003e Excipients:\u003cb\u003e ethyl alcohol\u003c\/b\u003e; \u003cb\u003epropylene glycol\u003c\/b\u003e; \u003cb\u003eperfume n.4074\u003c\/b\u003e; tris(hydroxymethyl)amino methane. \u003ci\u003e \u003cu\u003eSkin dust:\u003c\/u\u003e \u003c\/i\u003e Excipients: precipitated silica; \u003cb\u003eperfume n.4074\u003c\/b\u003e; zinc oxide; talc. \u003ci\u003e \u003cu\u003eSkin emulsion:\u003c\/u\u003e \u003c\/i\u003e Excipients: precipitated silica; mixture of stearic acid esters with glycols; mixture of fatty acids with polyethylene glycol; Vaseline oil; \u003cb\u003ebutylated hydroxyanisole; benzoic acid\u003c\/b\u003e; \u003cb\u003eperfume n.4074\u003c\/b\u003e; purified water. \u003ci\u003e \u003cu\u003eNon-alcoholic skin solution:\u003c\/u\u003e \u003c\/i\u003e Excipients: polysorbate 20; \u003cb\u003ebenzyl alcohol\u003c\/b\u003e; sorbitan monolaurate; N-[2-hydroxyethyl]-N-[2-(laurylamino)-ethyl] amino acetic acid sodium salt of 3,6,9-trioxadocosyl sulfate; polyoxyethylene glycol 6000 distearate; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients, listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL must be applied morning and evening, to the infected skin areas, with a light massage, until the mycosis completely disappears (1-3 weeks). It is advisable to continue the application of PEVARYL for a few days after the disappearance of the mycosis. Intertriginous spaces (e.g. interdigital spaces of the foot, folds of the buttocks) in the wet stage should be cleansed with gauze before applying PEVARYL. In the treatment of onychomycosis, an occlusive bandage is recommended. In the treatment of otomycosis (only if there is no lesion of the eardrum) instill 1-2 drops of PEVARYL skin emulsion 1-2 times a day, or insert a strip of gauze soaked in it into the external auditory canal. PEVARYL cutaneous powder should be used as complementary therapy to PEVARYL cream and alcoholic solution cutaneous spray. In the case of intertrigo, the use of PEVARYL cutaneous powder may be sufficient. PEVARYL non-alcoholic skin solution: sprinkle the entire damp body for three consecutive evenings, placing the product on a sponge; do not rinse. The drug takes effect during the night and must be removed by washing the following morning. If Pityriasis Versicolor has not been eradicated after 15 days from the end of the applications, repeat the treatment. To avoid relapses it is recommended to carry out the treatment again after 1 and 3 months. The regular and prescribed use of PEVARYL is of decisive importance for recovery.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEmulsion, skin spray, alcoholic solution and cream: store at a temperature not exceeding 25°C. Cutaneous powder: this medicinal product does not require any special storage conditions. PEVARYL, like any medicine, must be stored out of the reach of children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAll pharmaceutical forms of PEVARYL are indicated for external use only. PEVARYL is not for ophthalmic or oral use. In case of sensitization or irritation reaction, discontinue use of the product. Econazole nitrate powder contains talc. Avoid inhalation to prevent irritation of the airways, especially in children and infants. The application of the spray forms must be done avoiding inhaling the product and making excessive or improper use of it. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e. \u003cb\u003ePEVARYL1% cream contains butylated hydroxyanisole, benzoic acid and linalool:\u003c\/b\u003e This medicine contains butylated hydroxyanisole. May cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. This medicine contains 60 mg of benzoic acid in each 30 g tube which is equivalent to 2 mg\/g of cream. Benzoic acid may cause local irritation. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. This medicine contains a fragrance with linalool. Linalool can cause allergic reactions. \u003cb\u003ePEVARYL 1% skin spray, alcoholic solution contains propylene glycol and linalool\u003c\/b\u003e: This medicinal product contains 983.0 mg of propylene glycol per unit dose, which is equivalent to 491.5 mg\/g. Propylene glycol may cause local irritation. This medicine contains a fragrance with linalool. Linalool can cause allergic reactions. \u003cb\u003ePEVARYL 1% skin powder contains linalool\u003c\/b\u003e: This medicine contains a fragrance with linalool. Linalool can cause allergic reactions \u003cb\u003ePEVARYL 1% skin emulsion contains butylated hydroxyanisole, benzoic acid and linalool\u003c\/b\u003e: This medicinal product contains butylated hydroxyanisole. May cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. This medicine contains 60 mg of benzoic acid in each 30 g bottle which is equivalent to 2 mg\/g of cream. Benzoic acid may cause local irritation. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. This medicine contains a fragrance with linalool. Linalool can cause allergic reactions. \u003cb\u003ePEVARYL 1% non-alcoholic cutaneous solution contains benzyl alcohol\u003c\/b\u003e: This medicine contains 10 mg of benzyl alcohol in each sachet (10 mg), which is equivalent to 1 mg\/g. Benzyl alcohol may cause allergic reactions. Benzyl alcohol may cause mild local irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEconazole is a known inhibitor of cytochromes CYP3A4 and CYP2C9. Despite the limited systemic availability after cutaneous application, clinically relevant interactions with other medicinal products may occur and some have been reported in patients treated with oral anticoagulants, such as warfarin and acenocoumarol. In patients receiving oral anticoagulants, caution should be used and the INR should be monitored more frequently. A dosage adjustment of the oral anticoagulant drug may be necessary during treatment with econazole and after its discontinuation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eData from clinical studies:\u003c\/i\u003e \u003c\/b\u003e The safety of econazole nitrate cream (1%) and econazole nitrate emulsion (1%) was evaluated in 12 clinical studies involving 470 subjects, who received administration of at least one of the formulations. Based on the safety data collected from these clinical studies, the most commonly reported adverse drug reactions (ADRs) (incidence ≥ 1%) were (with incidence%): pruritus (1.3%), burning sensation of the skin (1.3%) and pain (1.1%). The ADRs reported with the use of PEVARYL dermatological formulations both in clinical studies, including the adverse reactions reported above, and in post-marketing experience are reported below. Frequencies are reported according to the following convention: Very common (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10); Municipality (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/100, \u003c1\/10); Uncommon (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/1,000, \u003c1\/100); Rare (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000), Not known (frequency cannot be estimated from the available data). In the table below, which shows the adverse reactions of the dermatological formulations of Pevaryl, all ADRs with a known incidence (common or uncommon) come from clinical trial data and all adverse reactions with an unknown incidence come from post-marketing data. \u003cb\u003eTable 1: Adverse Drug Reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse drug reactions: Frequency.\u003c\/p\u003e\n\u003cp\u003eSystem Organ Class - Adverse drug reactions: Common (≥ 1\/100, \u003c 1\/10). Uncommon (≥ 1\/1,000, \u003c 1\/100). Not Known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse drug reactions: Itching, burning sensation of the skin. Erythema. Angioedema, contact dermatitis, rash, urticaria, vesiculation, skin exfoliation.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse drug reactions: Pain. Malaise Swelling.\u003c\/p\u003e\n\u003cp\u003eThe use of products for topical use, especially if prolonged, can give rise to sensitization phenomena. In case of hypersensitivity reactions it is necessary to interrupt treatment and institute appropriate therapy. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe available pharmaceutical forms are intended exclusively for topical application. In case of accidental ingestion, nausea, vomiting and diarrhea may occur and must be treated with symptomatic therapy. If the product accidentally comes into contact with the eyes, wash with clean water or saline and contact a doctor if symptoms persist. \u003cu\u003ePevaryl 1% skin powder \u003c\/u\u003e The powder formulation contains talc: accidental massive aspiration of the dust can cause blockage of the airways, particularly in infants and children. Respiratory arrest should be treated with supportive therapy and oxygen. If breathing is compromised, the following measures should be considered: endotracheal intubation, removal of material and assisted ventilation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e: Animal studies have shown reproductive toxicity. The risk in humans is unknown. (see section 5.3) In humans, after topical application to intact skin, the systemic absorption of econazole is poor (\u003c 10%). There are no adequate and controlled studies, nor epidemiological data, on the side effects resulting from the use of PEVARYL during pregnancy. Due to systemic absorption, PEVARYL should not be used during the first trimester of pregnancy unless the doctor considers it necessary for the patient's health. PEVARYL can be used during the second and third trimesters of pregnancy if the potential benefit to the mother outweighs the possible risks to the fetus. \u003cb\u003eBreastfeeding\u003c\/b\u003e: After oral administration of econazole nitrate to lactating rats, econazole and\/or its metabolites were excreted in maternal milk and detected in the pups. It is not known whether cutaneous administration of PEVARYL can result in sufficient systemic absorption of econazole to produce detectable concentrations of econazole in human breast milk. Caution should be used when PEVARYL is administered to women during breastfeeding. \u003cb\u003eFertility\u003c\/b\u003e: Results from reproduction studies conducted in animals showed no effects on fertility (see section 5.3)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e","brand":"Karo Pharma","offers":[{"title":"Default Title","offer_id":51730205770055,"sku":"023603145","price":18.54,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/karo-pharma-srl-pevaryl-1-6-bustine-10-g-soluzione-cutanea-non-alcolica-farmacia-dottor-tili-1213791289.jpg?v=1767139709"},{"product_id":"pevaryl-1-30-g-polvere-cutanea","title":"Pevaryl 1% 30 g cutaneous powder","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL is indicated for the treatment of cutaneous candidiasis, dermatophytosis and pityriasis versicolor, including suspected concomitant infections with Gram-positive bacteria (see section 5.1).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePevaryl 1% cream 100 g of cream contain: active ingredient: econazole nitrate 1.0 g Excipients with known effects: butylated hydroxyanisole and benzoic acid Pevaryl 1% skin spray, alcoholic solution 100 g of alcoholic skin solution contain: active ingredient: econazole nitrate 1.0 g Excipients with known effects: ethanol, propylene glycol and Pevaryl perfume 1% skin powder 100 g of skin powder contain: active ingredient: econazole nitrate 1.0 g Excipient with known effects: perfume Pevaryl 1% skin emulsion 100 g of skin emulsion contain: active ingredient: econazole nitrate 1.0 g Excipients with known effects: butylated hydroxyanisole, benzoic acid and perfume For the full list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eCream\u003c\/u\u003e \u003c\/i\u003e Excipients: mixture of stearic acid esters with glycols; mixture of fatty acids with polyethylene glycol; Vaseline oil; \u003cb\u003eButylated hydroxyanisole\u003c\/b\u003e;\u003cb\u003e benzoic acid\u003c\/b\u003e; purified water. \u003ci\u003e \u003cu\u003eAlcoholic solution skin spray \u003c\/u\u003e \u003c\/i\u003e Excipients:\u003cb\u003e ethanol\u003c\/b\u003e; \u003cb\u003epropylene glycol\u003c\/b\u003e; \u003cb\u003eperfume (\u003c\/b\u003econtaining linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal\u003cb\u003e)\u003c\/b\u003e; tris(hydroxymethyl) amino methane. \u003ci\u003e \u003cu\u003eSkin dust\u003c\/u\u003e \u003c\/i\u003e Excipients: precipitated silica; \u003cb\u003eperfume (\u003c\/b\u003econtaining linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal); zinc oxide; talc. \u003ci\u003e \u003cu\u003eSkin emulsion\u003c\/u\u003e \u003c\/i\u003e Excipients: precipitated silica; mixture of stearic acid esters with glycols; mixture of fatty acids with polyethylene glycol; Vaseline oil; \u003cb\u003ebutylated hydroxyanisole; benzoic acid\u003c\/b\u003e; \u003cb\u003eperfume (\u003c\/b\u003econtaining linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal); purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients, listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL must be applied to the infected skin areas with a light massage 2 times a day, morning and evening. \u003cb\u003eThe usual duration of treatment is 2 to 4 weeks.\u003c\/b\u003e\u003ci\u003eIf no improvement in symptoms is noted after 4 weeks, treatment should be re-evaluated.\u003c\/i\u003e The intertriginous spaces (e.g. interdigital spaces of the foot, folds of the buttocks) in the wet stage must be cleansed with gauze before applying PEVARYL. In the case of intertrigo the use of PEVARYL cutaneous powder may be useful.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEmulsion, skin spray, alcoholic solution and cream: store below 25°C. Cutaneous powder: this medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAll pharmaceutical forms of PEVARYL are indicated for external use only. PEVARYL is not for ophthalmic or oral use. In case of sensitization or irritation reaction, discontinue use of the product. Econazole nitrate powder contains talc. Avoid inhalation to prevent irritation of the airways, especially in children and infants. The application of the spray forms must be done avoiding inhaling the product and making excessive or improper use of it. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003cb\u003ePEVARYL 1% cream contains butylated hydroxyanisole and benzoic acid.\u003c\/b\u003e This medicine contains butylated hydroxyanisole. May cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. This medicine contains 60 mg of benzoic acid in each 30 g tube which is equivalent to 2 mg\/g of cream. Benzoic acid may cause local irritation. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. \u003cb\u003ePEVARYL 1% skin spray, alcoholic solution contains ethanol, propylene glycol and perfume.\u003c\/b\u003e This medicine contains 49.5% ethanol, equivalent to 0.495 mg\/ml. May cause burning sensation on damaged skin. This medicinal product contains 983.0 mg of propylene glycol per unit dose, which is equivalent to 491.5 mg\/g. Propylene glycol may cause local irritation. This medicine contains a fragrance which in turn contains linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal. Linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, Farnesol, benzyl alcohol and cinnamal can cause allergic reactions. \u003cb\u003ePEVARYL 1% skin powder contains perfume\u003c\/b\u003e This medicine contains a fragrance which in turn contains linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal. Linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, Farnesol, benzyl alcohol and cinnamal can cause allergic reactions. \u003cb\u003ePEVARYL 1% skin emulsion contains butylated hydroxyanisole, benzoic acid and perfume\u003c\/b\u003e This medicine contains butylated hydroxyanisole. It may cause localized skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. This medicine contains 60 mg of benzoic acid in each 30 g bottle which is equivalent to 2 mg\/g of cream. Benzoic acid may cause local irritation. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. This medicine contains a fragrance which in turn contains linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal. Linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, Farnesol, benzyl alcohol and cinnamal can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEconazole is a known inhibitor of cytochromes CYP3A4 and CYP2C9. Despite the limited systemic availability after cutaneous application, clinically relevant interactions with other medicinal products may occur and some have been reported in patients treated with oral anticoagulants, such as warfarin and acenocoumarol. In patients receiving oral anticoagulants, caution should be used and the INR should be monitored more frequently. A dosage adjustment of the oral anticoagulant drug may be necessary during treatment with econazole and after its discontinuation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse drug reactions (Adverse Drug Reactions, ADRs) reported with the use of the different dermatological formulations of PEVARYL both in clinical studies and in post-marketing experience are listed below. \u003cb\u003eData deriving from clinical studies\u003c\/b\u003e The safety of econazole nitrate cream (1%) and econazole nitrate emulsion (1%) was evaluated in 12 clinical studies involving 470 subjects, who received administration of at least one of the formulations. Based on the safety data collected from these clinical studies, the most commonly reported ADRs (incidence ≥ 1%) were (with incidence): pruritus (1.3%), burning sensation of the skin (1.3%) and pain (1.1%). In the table below, which shows the adverse reactions of the dermatological formulations of Pevaryl, all ADRs with a known incidence (common or uncommon) are from clinical trial data and all adverse reactions with an unknown incidence are from post-marketing data. Frequencies are reported according to the following convention: Very common (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10); Municipality (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/100, \u003c1\/10); Uncommon (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/1,000, \u003c1\/100); Rare (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000), Not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1: Adverse Drug Reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse drug reactions: Frequency.\u003c\/p\u003e\n\u003cp\u003eSystem Organ Class - Adverse drug reactions: Common (≥ 1\/100, \u003c 1\/10). Uncommon (≥ 1\/1,000, \u003c 1\/100). Not Known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse drug reactions: Itching, burning sensation of the skin. Erythema. Angioedema, contact dermatitis, rash, urticaria, vesiculation, skin exfoliation.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse drug reactions: Pain. Malaise Swelling.\u003c\/p\u003e\n\u003cp\u003eThe use of products for topical use, especially if prolonged, can give rise to sensitization phenomena. In case of hypersensitivity reactions it is necessary to interrupt treatment and institute appropriate therapy. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe available pharmaceutical forms are intended exclusively for topical application. In case of accidental ingestion, nausea, vomiting and diarrhea may occur and must be treated with symptomatic therapy. If the product accidentally comes into contact with the eyes, wash with clean water or saline and contact a doctor if symptoms persist. \u003cu\u003ePevaryl 1% skin powder \u003c\/u\u003e The powder formulation contains talc: accidental massive aspiration of the dust can cause blockage of the airways, particularly in infants and children. Respiratory arrest should be treated with supportive therapy and oxygen. If breathing is compromised, the following measures should be considered: endotracheal intubation, removal of material and assisted ventilation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e Animal studies have shown reproductive toxicity. The risk in humans is unknown. (see paragraph 5.3). In humans, after topical application on intact skin, the systemic absorption of econazole is poor (\u003c 10%). There are no adequate and controlled studies, nor epidemiological data, on the side effects resulting from the use of PEVARYL during pregnancy. Due to systemic absorption, PEVARYL should not be used during the first trimester of pregnancy unless the doctor considers it necessary for the patient's health. PEVARYL can be used during the second and third trimesters of pregnancy if the potential benefit to the mother outweighs the possible risks to the fetus. \u003cb\u003eBreastfeeding\u003c\/b\u003e After oral administration of econazole nitrate to lactating rats, econazole and\/or its metabolites were excreted in maternal milk and detected in the pups. It is not known whether cutaneous administration of PEVARYL can result in sufficient systemic absorption of econazole to produce detectable concentrations of econazole in human breast milk. Caution should be used when PEVARYL is administered to women during breastfeeding. \u003cb\u003eFertility\u003c\/b\u003e Results from reproduction studies conducted in animals showed no effects on fertility (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e","brand":"Karo Pharma","offers":[{"title":"Default Title","offer_id":51730205868359,"sku":"023603044","price":15.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/karo-pharma-srl-pevaryl-1-30-g-polvere-cutanea-farmacia-dottor-tili-1213791368.jpg?v=1767139786"},{"product_id":"pevaryl-1-30-g-crema","title":"Pevaryl 1% 30g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL is indicated for the treatment of cutaneous candidiasis, dermatophytosis and pityriasis versicolor, including suspected concomitant infections with Gram-positive bacteria (see section 5.1).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePevaryl 1% cream 100 g of cream contain: active ingredient: econazole nitrate 1.0 g Excipients with known effects: butylated hydroxyanisole and benzoic acid Pevaryl 1% skin spray, alcoholic solution 100 g of alcoholic skin solution contain: active ingredient: econazole nitrate 1.0 g Excipients with known effects: ethanol, propylene glycol and Pevaryl perfume 1% skin powder 100 g of skin powder contain: active ingredient: econazole nitrate 1.0 g Excipient with known effects: perfume Pevaryl 1% skin emulsion 100 g of skin emulsion contain: active ingredient: econazole nitrate 1.0 g Excipients with known effects: butylated hydroxyanisole, benzoic acid and perfume For the full list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eCream\u003c\/u\u003e \u003c\/i\u003e Excipients: mixture of stearic acid esters with glycols; mixture of fatty acids with polyethylene glycol; Vaseline oil; \u003cb\u003eButylated hydroxyanisole\u003c\/b\u003e;\u003cb\u003e benzoic acid\u003c\/b\u003e; purified water. \u003ci\u003e \u003cu\u003eAlcoholic solution skin spray \u003c\/u\u003e \u003c\/i\u003e Excipients:\u003cb\u003e ethanol\u003c\/b\u003e; \u003cb\u003epropylene glycol\u003c\/b\u003e; \u003cb\u003eperfume (\u003c\/b\u003econtaining linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal\u003cb\u003e)\u003c\/b\u003e; tris(hydroxymethyl) amino methane. \u003ci\u003e \u003cu\u003eSkin dust\u003c\/u\u003e \u003c\/i\u003e Excipients: precipitated silica; \u003cb\u003eperfume (\u003c\/b\u003econtaining linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal); zinc oxide; talc. \u003ci\u003e \u003cu\u003eSkin emulsion\u003c\/u\u003e \u003c\/i\u003e Excipients: precipitated silica; mixture of stearic acid esters with glycols; mixture of fatty acids with polyethylene glycol; Vaseline oil; \u003cb\u003ebutylated hydroxyanisole; benzoic acid\u003c\/b\u003e; \u003cb\u003eperfume (\u003c\/b\u003econtaining linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal); purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients, listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePEVARYL must be applied to the infected skin areas with a light massage 2 times a day, morning and evening. \u003cb\u003eThe usual duration of treatment is 2 to 4 weeks.\u003c\/b\u003e\u003ci\u003eIf no improvement in symptoms is noted after 4 weeks, treatment should be re-evaluated.\u003c\/i\u003e The intertriginous spaces (e.g. interdigital spaces of the foot, folds of the buttocks) in the wet stage must be cleansed with gauze before applying PEVARYL. In the case of intertrigo the use of PEVARYL cutaneous powder may be useful.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEmulsion, skin spray, alcoholic solution and cream: store below 25°C. Cutaneous powder: this medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAll pharmaceutical forms of PEVARYL are indicated for external use only. PEVARYL is not for ophthalmic or oral use. In case of sensitization or irritation reaction, discontinue use of the product. Econazole nitrate powder contains talc. Avoid inhalation to prevent irritation of the airways, especially in children and infants. The application of the spray forms must be done avoiding inhaling the product and making excessive or improper use of it. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003cb\u003ePEVARYL 1% cream contains butylated hydroxyanisole and benzoic acid.\u003c\/b\u003e This medicine contains butylated hydroxyanisole. May cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. This medicine contains 60 mg of benzoic acid in each 30 g tube which is equivalent to 2 mg\/g of cream. Benzoic acid may cause local irritation. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. \u003cb\u003ePEVARYL 1% skin spray, alcoholic solution contains ethanol, propylene glycol and perfume.\u003c\/b\u003e This medicine contains 49.5% ethanol, equivalent to 0.495 mg\/ml. May cause burning sensation on damaged skin. This medicinal product contains 983.0 mg of propylene glycol per unit dose, which is equivalent to 491.5 mg\/g. Propylene glycol may cause local irritation. This medicine contains a fragrance which in turn contains linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal. Linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, Farnesol, benzyl alcohol and cinnamal can cause allergic reactions. \u003cb\u003ePEVARYL 1% skin powder contains perfume\u003c\/b\u003e This medicine contains a fragrance which in turn contains linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal. Linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, Farnesol, benzyl alcohol and cinnamal can cause allergic reactions. \u003cb\u003ePEVARYL 1% skin emulsion contains butylated hydroxyanisole, benzoic acid and perfume\u003c\/b\u003e This medicine contains butylated hydroxyanisole. It may cause localized skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. This medicine contains 60 mg of benzoic acid in each 30 g bottle which is equivalent to 2 mg\/g of cream. Benzoic acid may cause local irritation. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. This medicine contains a fragrance which in turn contains linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, farinasol, benzyl alcohol and cinnammal. Linalool, citronellol, 3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, geraniol, hydroxycitronellal, coumarin, benzyl salicylate, hexyl cinnamic aldehyde, d-Limonene, citral, cinnamyl alcohol, lilial, eugenol, benzyl beanzoate, isoeugenol, Farnesol, benzyl alcohol and cinnamal can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEconazole is a known inhibitor of cytochromes CYP3A4 and CYP2C9. Despite the limited systemic availability after cutaneous application, clinically relevant interactions with other medicinal products may occur and some have been reported in patients treated with oral anticoagulants, such as warfarin and acenocoumarol. In patients receiving oral anticoagulants, caution should be used and the INR should be monitored more frequently. A dosage adjustment of the oral anticoagulant drug may be necessary during treatment with econazole and after its discontinuation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse drug reactions (Adverse Drug Reactions, ADRs) reported with the use of the different dermatological formulations of PEVARYL both in clinical studies and in post-marketing experience are listed below. \u003cb\u003eData deriving from clinical studies\u003c\/b\u003e The safety of econazole nitrate cream (1%) and econazole nitrate emulsion (1%) was evaluated in 12 clinical studies involving 470 subjects, who received administration of at least one of the formulations. Based on the safety data collected from these clinical studies, the most commonly reported ADRs (incidence ≥ 1%) were (with incidence): pruritus (1.3%), burning sensation of the skin (1.3%) and pain (1.1%). In the table below, which shows the adverse reactions of the dermatological formulations of Pevaryl, all ADRs with a known incidence (common or uncommon) are from clinical trial data and all adverse reactions with an unknown incidence are from post-marketing data. Frequencies are reported according to the following convention: Very common (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10); Municipality (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/100, \u003c1\/10); Uncommon (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/1,000, \u003c1\/100); Rare (\u003cb\u003e \u003ci\u003e≥\u003c\/i\u003e \u003c\/b\u003e1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000), Not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1: Adverse Drug Reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse drug reactions: Frequency.\u003c\/p\u003e\n\u003cp\u003eSystem Organ Class - Adverse drug reactions: Common (≥ 1\/100, \u003c 1\/10). Uncommon (≥ 1\/1,000, \u003c 1\/100). Not Known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse drug reactions: Itching, burning sensation of the skin. Erythema. Angioedema, contact dermatitis, rash, urticaria, vesiculation, skin exfoliation.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse drug reactions: Pain. Malaise Swelling.\u003c\/p\u003e\n\u003cp\u003eThe use of products for topical use, especially if prolonged, can give rise to sensitization phenomena. In case of hypersensitivity reactions it is necessary to interrupt treatment and institute appropriate therapy. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe available pharmaceutical forms are intended exclusively for topical application. In case of accidental ingestion, nausea, vomiting and diarrhea may occur and must be treated with symptomatic therapy. If the product accidentally comes into contact with the eyes, wash with clean water or saline and contact a doctor if symptoms persist. \u003cu\u003ePevaryl 1% skin powder \u003c\/u\u003e The powder formulation contains talc: accidental massive aspiration of the dust can cause blockage of the airways, particularly in infants and children. Respiratory arrest should be treated with supportive therapy and oxygen. If breathing is compromised, the following measures should be considered: endotracheal intubation, removal of material and assisted ventilation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e Animal studies have shown reproductive toxicity. The risk in humans is unknown. (see paragraph 5.3). In humans, after topical application on intact skin, the systemic absorption of econazole is poor (\u003c 10%). There are no adequate and controlled studies, nor epidemiological data, on the side effects resulting from the use of PEVARYL during pregnancy. Due to systemic absorption, PEVARYL should not be used during the first trimester of pregnancy unless the doctor considers it necessary for the patient's health. PEVARYL can be used during the second and third trimesters of pregnancy if the potential benefit to the mother outweighs the possible risks to the fetus. \u003cb\u003eBreastfeeding\u003c\/b\u003e After oral administration of econazole nitrate to lactating rats, econazole and\/or its metabolites were excreted in maternal milk and detected in the pups. It is not known whether cutaneous administration of PEVARYL can result in sufficient systemic absorption of econazole to produce detectable concentrations of econazole in human breast milk. Caution should be used when PEVARYL is administered to women during breastfeeding. \u003cb\u003eFertility\u003c\/b\u003e Results from reproduction studies conducted in animals showed no effects on fertility (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e","brand":"Karo Pharma","offers":[{"title":"Default Title","offer_id":51730207834439,"sku":"023603018","price":15.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/karo-pharma-srl-pevaryl-1-30-g-crema-farmacia-dottor-tili-1213791087.jpg?v=1767140508"}],"url":"https:\/\/www.dottortili.com\/en\/collections\/pevaryl.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}